A bivalent lysine-acetylated small-molecule binding site in MYC
Authors:
- Dikshat G. GuptaDikshat G. Gupta
- Mihai I. TruicaMTMihai I. Truica
- Adam W.T. SteffeckASAdam W.T. Steffeck
- J. Brandon ParkerJPJ. Brandon Parker
- Daniel H. RyanDRDaniel H. Ryan
- Hao PanHPHao Pan
- William YangWYWilliam Yang
- Xinyan LuXLXinyan Lu
- Kenji UnnoKUKenji Unno
- Songhua QuanSQSonghua Quan
- Ala A. ElmashaeAEAla A. Elmashae
- Megan M. KerberMKMegan M. Kerber
Preprint
Abstract
MYC is an important, yet challenging target in oncology as it lacks traditional “druggable” pockets. Here we show that two regions of the MYC protein, the basic-Helix-Loop-Helix (bHLH) domain, and an extended MYC Box II (eMBII) come together to form a bivalent, high-affinity small-molecule MYC inhibitor (MYCi) binding site. CRISPR-tiling mutagenesis identified mutations in the vicinity of emBII and in bHLH regions that together confer MYCi resistance. Importantly, acetylation of lysine K148 in eMBII which is essential for MYC oncogenicity in vivo increased the predicted order of this region and enhanced MYCi binding affinity. Furthermore, MYCi selectively modulated the expression of the same genes regulated by lysine-acetylated MYC in cancer cells. These studies provide a rationale for the selective targeting of acetylated, oncogenic MYC with small molecules.Keywords
Funding Information
- National Institutes of Health (P50 CA180995)
- National Institutes of Health (R01 CA257258)
- National Institutes of Health (R35 GM143054)
- Prostate Cancer Foundation (PCF) TACTICAL Award
- Polsky Urologic Cancer Institute
This publication has 48 references indexed in Scilit:
- Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposuresCancer Cell, 2025
- Multi-scale signaling and tumor evolution in high-grade gliomasCancer Cell, 2024
- Proteogenomic insights suggest druggable pathways in endometrial carcinomaCancer Cell, 2023
- Proteogenomic and metabolomic characterization of human glioblastomaCancer Cell, 2021
- Proteogenomic Characterization of Endometrial CarcinomaCell, 2020
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance ImmunotherapyCancer Cell, 2019
- Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP/p300 AcetylomeCell, 2018
- Expression and Purification of Site-Specifically Lysine-Acetylated and Natively-Folded Proteins for Biophysical Investigations2018
- MYC on the Path to CancerCell, 2012
- Six lysine residues on c-Myc are direct substrates for acetylation by p300Biochemical and Biophysical Research Communications, 2005